{"id":"W3095487872","doi":"10.1182/blood-2020-136751","title":"Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; London Health Sciences Centre; Western University; Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Health Sciences Centre; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Pembrolizumab; Population; Immunotherapy; Regimen; Chemotherapy regimen; Chimeric antigen receptor; Cyclophosphamide; Immunology; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001976436,0.001124388,0.001761491,0.0004702525,0.0002129521,0.0008087438,0.0007947005,0.0007725128,0.002626108],"category_scores_gemma":[0.0006992632,0.0003390682,0.001209529,0.0002642678,0.000595042,0.0007011978,0.0005583416,0.001526636,0.0006503202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008188164,"about_ca_system_score_gemma":0.0007481267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004158444,"about_ca_topic_score_gemma":0.0009928496,"domain_scores_codex":[0.9993494,0.0003607137,0.00004015195,0.00009530165,0.00009003862,0.00006432659],"domain_scores_gemma":[0.9994273,0.0001091239,0.000116333,0.00006498802,0.00004830001,0.0002340538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6415352,0.04388338,0.01313575,0.001560668,0.006805992,0.0003508203,0.0003339363,0.00444122,0.05582415,0.0003498705,0.00418589,0.2275932],"study_design_scores_gemma":[0.2036852,0.751757,0.02952463,0.00008644873,0.002098053,0.000376339,0.0001210306,0.001600914,0.005826629,0.0001615177,0.004708315,0.00005398171],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928157,0.00353627,0.0001960757,0.0002627978,0.00007672542,0.0003060964,0.0004532524,0.00006794158,0.002285126],"genre_scores_gemma":[0.9955734,0.001180618,0.0003780289,0.000248368,0.0001017295,0.0002717387,0.0009140281,0.00001154374,0.001320513],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002626108,"threshold_uncertainty_score":0.01045251,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03329050655822488,"score_gpt":0.350969610565984,"score_spread":0.3176791040077591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}